U.S. Cancer-Specific Mortality Trends After Early Immune Checkpoint Inhibitor Approvals: An Ecological Synthetic-Control Study, 1999-2019.

Authors

Woo Joo Lee, Seon Hye Won, Robin Park, Muhammad Sohaib Asghar, Moazzam Shahzad, Thomas Shimshak

Published in

Cancer control : journal of the Moffitt Cancer Center. Volume 33. Pages 10732748261492471. Epub Oct 07, 2026.

Abstract

IntroductionImmune checkpoint inhibitors (ICIs) were introduced at different times across cancer types, but whether early approvals coincided with cancer-specific changes in national mortality remains uncertain.MethodsWe conducted an ecological observational comparative time-series study using CDC WONDER United States Cancer Statistics mortality data from 1999-2019. We analyzed CDC-calculated age-adjusted mortality rates (AAMRs) for melanoma of the skin, lung and bronchus, kidney and renal pelvis, urinary bladder, and Hodgkin lymphoma. Cancer-specific synthetic-control models used each site's first major ICI approval year, preperiod-centered log AAMR trajectories, mutually exclusive solid or hematologic comparison sites, and a common 0-3-year postapproval estimand. Placebo analyses and staggered-adoption difference-in-differences (DiD) were robustness checks.ResultsObserved AAMRs averaged 3.44%, 13.05%, 4.73%, 3.60%, and 3.68% below synthetic estimates for melanoma, lung, kidney, bladder, and Hodgkin lymphoma, respectively. Conditional placebo-rank pseudo-P values were .40, .23, .25, .20, and 1.00. Temporal-placebo models showed earlier divergence for several sites. The balanced 0-3-year DiD estimate was -0.96 deaths per 100,000 (95% pointwise CI, -2.99 to 1.06).ConclusionCancer-specific mortality patterns were directionally compatible with lower mortality during early ICI approval eras, but placebo benchmarking, heterogeneous temporal specificity, and an imprecise DiD estimate precluded firm causal attribution. These ecological findings do not estimate individual treatment effectiveness or current ICI practice.

PMID:
42842875
Bibliographic data and abstract were imported from PubMed on 08 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.